Background: Culture-negative AOM is often milder and associated with lower local/systemic inflammatory responses than culture-positive AOM. Study Objectives: To compare the clinical outcome of culture-negative AOM with that of culture-positive AOM children. Patients and Methods: Children aged 3 to 35 months with AOM were enrolled in 11 double-tympanocentesis antibiotic efficacy studies documenting both bacteriologic (days 4 -6 of treatment) and clinical outcome (days 11-14, end of treatment). Univariate analysis (age, gender, ethnicity, previous AOM history, and antibiotic treatment) between culture-negative and culture-positive AOM patients was performed by Student t test, ANOVA, or 2 test. Those found to be significant were further submitted to multivariable regression analysis. Results: A total of 1088 patients (mean age, 11.95 Ϯ 5.96 months, 209 culture-negative and 879 culture-positive AOM) were enrolled. No differences were recorded between culture-negative AOM and culture-positive AOM patients in age, gender, ethnicity and number of previous episodes. Seventy-four percent (650/879) culture-positive AOM patients achieved bacteriologic eradication within 3 to 5 days. Successful outcome (cured ϩ improved) was recorded in 90% (189/209) culture-negative AOM patients versus 86% (758/879) in culture-positive AOM (P ϭ 0.086). Successful clinical outcome was more frequent in culture-negative than in culturepositive AOM without bacteriologic eradication (90% vs. 67% ͓154/229͔, P Ͻ 0.001). No difference in successful clinical outcome was found between culture-negative versus culture-positive AOM patients with bacterial eradication (90% vs. 93% ͓604/650͔, P ϭ 0.24). Overall, the inclusion of culture-negative AOM patients in the evaluation of clinical failures rates in study patients decreased the total clinical failure rate by 9%. We present a hypothetical antibiotic efficacy study enrolling 300 patients in whom 2 drugs with different bacteriologic efficacy rates (A-90% and B-60%) were used. When the culture-negative cases (5% clinical failure) enrolled increased from 50/300 (16.7%) to 150/300 (50%), the overall clinical failure rate decreased by 36% (from 17.4% to 11.2%, P ϭ 0.08) for the less efficacious drug, while remaining unmodified for the more efficacious drug (9.6% and 8.8%, respectively). Conclusions: (1) Clinical outcome in culture-negative AOM was similar to that of culture-positive AOM with bacteriologic eradication and both were superior to that of culture-positive AOM without eradication; (2) Inclusion of culture-negative AOM patients in series aiming at antibiotic efficacy may falsely improve the clinical outcome for antibiotics with reduced ability to eradicate AOM pathogens.
A cute otitis media (AOM) is generally considered to be a bacterial disease, although approximately 10% to 30% of the patients do not have bacteria isolated from the middle ear fluid (MEF).
1,2 Culture-negative AOM may be a result of technical problems in obtaining, handling, and culturing the MEF, prior antibiotic treatments, titer of organisms below the limit of detectability, presence of biofilms where the organisms survive at a very low metabolic and cell-division rate or a viral etiology. [3] [4] [5] [6] [7] [8] [9] Clinical and laboratory data suggest that culture-negative AOM is a different entity compared with culture-positive AOM. Previous reports demonstrated that the MEF neutrophil counts as well as the inflammatory process present in the MEF of patients with AOM, as measured by TNF-␣ and interleukins 1, 6 , and 8 concentrations, were significantly lower in culturenegative AOM patients compared with culture-positive patients. 10 -13 Furthermore, when a clinical-otologic evaluation score (measuring patient fever and irritability, and tympanic membrane redness and bulging) was used, culture-positive AOM was associated with a significantly higher disease severity score compared with culture-negative AOM. 14 In clinical practice, antibiotic drugs are often prescribed for AOM without performing any etiologic microbiologic tests. 15 Therefore, many culture-negative patients will receive antibiotic therapy.
The objectives of the present study were (1) to compare the demographic characteristics and the clinical outcome of patients with culture-negative AOM with those of culture-positive AOM patients and (2) to assess whether combining the clinical responses of patients with culture-positive AOM with those with culturenegative AOM might affect the clinical outcome analysis in antibiotic efficacy studies.
Data from the study evaluating the efficacy of trimethoprim/sulfamethoxazole 28 and the arm of amoxicillin/clavulanate 45/6.4 mg/kg/bid from study 4 22 was excluded from the analysis due to insufficient number of evaluable patients with culture-negative AOM (2 and 0, respectively). The final analysis includes therefore data from patients enrolled in 11 double tympanocentesis studies (Table 1) . Six studies included patients not treated with antibiotics at enrolment for Ն7 days, while 1 study (5) allowed inclusion of patients treated with antibiotics within 7 days of enrolment provided treatment was started Ն48 hours before enrolment without clinical improvement. Studies 2, 8, 10, and 11 allowed free patient enrolment regardless prior antibiotic treatment, but 2 of them (8 and 10) required enrolment of untreated patients only if they had a history of recurrent AOM (Ͼ3 AOM episodes).
Patients
AOM was diagnosed if patients had symptoms and signs consistent with AOM (fever, irritability, or tugging of the ears together with redness, bulging, or blurring of tympanic membrane anatomic landmarks and illness of Ͻ7 days duration. The studies included children: (1) diagnosed as having AOM; (2) aged 3 to 35 months; (3) with a second MEF culture performed after 3 to 5 days of treatment (days 4 -6) in those patients reported culture-positive MEF at enrollment; (4) available for the post-treatment clinical outcome examination (days [11] [12] [13] [14] ; and (5) compliant with the protocol.
Children were excluded if spontaneous tympanic membrane perforation occurred Ͼ24 hours before enrolment and if tympanostomy tubes were present.
When evaluating the effect of prior antibiotic treatment on the positivity of the MEF culture at enrolment and of MEF culture results at enrollment on the clinical outcome at the end of therapy visit, all the patients treated with cefaclor (2 studies), amoxicillin/ clavulanate (2) and azithromycin (3) were pooled together. In addition, patients treated with cefuroxime axetil and cefdinir (second generation cephalosporins with similar antimicrobial activity) were pooled together to reach an evaluable number of culturenegative patients.
Study Conduct and Criteria for Evaluation
Tympanocentesis for culture was performed at study entry and repeated on days 4 to 6 (for patients with positive culture-MEF at visit 1) by an otolaryngologist under microscopy as described previously. 3 Bacteriologic response on days 4 to 6 was defined as successful if the culture from the second tympanocentesis was negative or if no MEF could be aspirated. Bacteriologic failure was defined as failure to eliminate the initial pathogen or the appearance of a new pathogen on days 4 to 6 (in initially culturepositive patients) or appearance of a pathogen in the MEF on days 4 to 6 in initially culture-negative patients (who were considered clinical failures on days 4 to 6 and required tympanocentesis). 
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Clinical failure was defined as no improvement of signs and symptoms after Ն48 hours of therapy requiring the use of an alternative antibiotic drug. This could occur at any time before or on the day 11 to 14 visit (end of therapy visit).
The middle ear findings at all visits (tympanic membrane redness, opacity, bulging) were determined by an otolaryngologist, using microscopic examination. The otolaryngologist was neither aware of the administered drug nor of the culture findings at any stage. Patients with treatment modification before the second tympanocentesis were excluded from the study. Patients with purulent ear discharge at end of therapy were considered clinical failure even if improved in other clinical parameters.
All study drugs were administered as oral suspension except for ceftriaxone, which was administered intramuscularly. Antibiotic treatment was completed for its whole duration, per protocol, in both culture-positive and culture-negative patients.
Microbiology
Middle ear fluid samples were transported to the Clinical Microbiology Laboratories and processed within 16 hours as previously described. 17 The study pathogens were defined as one of the following: Streptococcus pneumoniae, non typeable Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pyogenes.
Statistical Methods
Data were analyzed using SPSS 12.0 software (Chicago, IL). Univariate analysis (age, gender, ethnicity, previous AOM history, and previous antibiotic treatment) between culture-negative and culture-positive AOM patients was performed by Student t test, ANOVA or 2 test. Those parameters found to be significant were further submitted to multivariable regression analysis. A P Ͻ 0.05 was considered statistically significant.
RESULTS
During the period 1994 -2004, 1453 patients were enrolled in 11 double-tympanocentesis studies and 1088 were evaluable for analysis of bacteriologic and clinical outcome (completed 3 visits, on day 1, days 4 -6, and days [11] [12] [13] [14] . Of these 879 (81%) had culture-positive AOM and 209 (19%) had culture-negative AOM at enrolment.
There were 580 (53%) males (449, 51% and 131, 63%, in culture-positive and culture-negative patients, respectively, P ϭ 0.003). No differences were recorded between the culturepositive and culture-negative AOM patients in respect to age, ethnicity and previous number of AOM episodes. The mean Ϯ SD age of the patients was 12.00 Ϯ 6.0 months (11.9 Ϯ 5.9 for culture-positive and 12.0 Ϯ 6.1 for culture-negative patients, respectively). No differences were also recorded between the ages of patients who achieved bacterial eradication compared with those with bacteriologic failure on days 4 to 6 (11.9 Ϯ 6.0 and 12.2 Ϯ 5.9, respectively). The youngest patients (mean age, 9.3 Ϯ 5.4 months) were those enrolled in the study evaluating the efficacy of amoxicillin 80 mg/kg/d (study 7) and the oldest were those enrolled in the study evaluating the efficacy of levofloxacin (mean age, 14.0 Ϯ 6.6 months). Overall, 621 (57%) patients were Ͻ1 years old (506, 57% and 115, 55%, among culture-positive and culturenegative AOM patients, respectively); 1027 (94%) were Ͻ2 years old. Five hundred (46%) of the 1081 evaluable patients were Jewish children and 581 were Bedouin children. Overall, 270/1079 (25%) evaluable patients had their first AOM episode at enrolment (228/876, 26% and 42/203, 20%, among culture-positive and culture-negative AOM patients, respectively, P ϭ 0.01). Four hundred fifty (51%) of the 876 evaluable culture-positive patients and 110/203 (54%) evaluable culture-negative patients had Ն3 previous AOM episodes before enrolment. Six hundred forty-one (59%) patients had bilateral ear involvement; more patients in the culture-positive group had bilateral AOM than in the culture-negative group (547/879, 62% vs. 94/209, 45%, respectively, P Ͻ 0.001).
The distribution of culture-negative patients as function of the antibiotic treatment prescribed during the 7 days preceding enrolment is presented in Table, Supplemental Digital Content 1, http://links.lww.com/INF/A301. Of the 206/209 culture-negative patients for whom data was available, 88 did not receive any antibiotics during the 7 days preceding enrollment with AOM. There were no significant differences between the untreated culture-negative patients ("true" culture-negative patients) compared with the antibiotics-treated culture-negative patients in respect to gender, ethnicity, age (mean Ϯ SD), and laterality of the disease. Significantly more evaluable patients in the "true" culture-negative patients did not have previous AOM episodes compared with the antibiotics-treated culture-negative patients (28/84, 33% vs. 14/ 116, 12%, P Ͻ 0.001).
Significantly more evaluable culture-negative patients received antibiotic treatment during the 72 hours before enrolment than culture-positive patients (105/206, 51% vs. 253/869, 29%, P Ͻ 0.001)- On day 11 to 14 visit (end of therapy), 947/1088 (87%) patients had a successful clinical outcome (Table 2) -results following multivariate analysis and correcting for age, ethnicity, previous AOM history and previous number of AOM episodes). The highest rates of successful clinical outcome were recorded in the studies using levofloxacin, gatifloxacin and amoxicillin/clavulanate (99%, 95%, and 93%, respectively). Six hundred fifty (74%) of the 879 patients with culture-positive AOM achieved bacteriologic eradication on days 4 to 6 of therapy. The overall rate of successful clinical outcome was 90% (189/209) in culture-negative AOM patients compared with 86% (758/879) in culture-positive AOM patients (P ϭ 0.1). Culture-negative AOM patients had a higher rate of successful clinical outcome compared with culturepositive AOM patients without successful bacteriological outcome (90% ͓189/209͔ vs. 67% ͓154/229͔, P Ͻ 0.001). No differences were found between the rates of successful clinical outcome recorded in culture-negative AOM patients and those recorded in culturepositive AOM patients who achieved successful bacteriological outcome (90% ͓189/209͔ vs. 93% ͓604/650͔, P ϭ 0.24). No differences were found between the rates of successful clinical outcome recorded in evaluable culture-negative AOM patients who received antibiotic treatment during the 72 hours prior to enrolment and those recorded in evaluable culture-negative AOM patients who did not receive antibiotic treatment prior to enrollment (89% ͓93/105͔ vs. 93% ͓94/101͔, P ϭ 0.26). No differences were found between the rates of successful clinical outcome recorded in evaluable culture-negative AOM patients who did not receive any antibiotic treatment during the 7 days prior to enrolment and those recorded in evaluable culture-negative AOM patients who did receive antibiotic treatment during the 7 days prior to enrolment (94% ͓83/88͔ vs. 88% ͓104/118͔, P ϭ 0.13).
Overall, the inclusion of culture-negative AOM patients in the evaluation of clinical failures rates in study patients decreased the total clinical failure rate by 9% (from 14% ͓culture-positive patients only͔ to 13% (all patients)- Table 2 . The respective numbers were 14%, 10%, 9%, and 6% in the studies evaluating the 5%) enrolled in the study increased from 50/300 (16.7%) to 150/300 (50%), the overall clinical failure rate decreased by 36% (from 17.4% to 11.2%, P ϭ 0.08) for the less efficacious drug while remaining unmodified for the more efficacious drug (9.6% and 8.8%, respectively). When culture-negative cases constituted 50% of all patients, the overall rate of clinical failure increased only by 53% (from 7.3% to 11.2%) when using drug B instead of drug A, compared with 81% (from 9.6% to 17.4%) when enrolling only culture-positive patients.
DISCUSSION
The present study highlights several important points: (1) There were no significant demographic, epidemiologic, and medical past history-related differences between culture-negative and culture-positive AOM patients; (2) Patients recently treated with antibiotics had significantly higher rates of negative MEF cultures compared with those not treated previously with antibiotics; (3) Patients with culture-negative AOM had a similar clinical outcome compared with those with culture-positive AOM associated with bacteriologic eradication; (4) Both culture-negative patients and patients with culture-positive AOM with bacterial eradication had a superior clinical outcome compared with patients with culturepositive AOM without eradication.
The clinical outcome in culture-negative AOM patients was constantly favorable (90% cure or improvement), whereas that in culture-positive patients depended on the bacteriologic outcome, with a clearly superior outcome in those patients who achieved eradication compared with those without eradication. The clinical outcome in culture-negative patients was similar to that of culturepositive patients treated with potent antibiotic drugs who eradicated the MEF pathogens.
AOM treatment guidelines are based, among other factors, on the published results of efficacy studies. 15 In most of these studies, completion of the antibiotic treatment according to the study protocol was required, regardless of the MEF cultures results available, resulting in administration of a full antibiotic course even in culturenegative patients. Furthermore, when evaluating and reporting the results of the studies, the analysis of the clinical outcome was made, in general, without differentiating between initially culture-negative or culture-positive AOM patients. This creates an interpretation bias, overemphasizing the successful outcome of children treated with antibiotics that have low bacteriologic activity.
The importance of using microbiologically effective antibiotics associated with bacterial eradication of MEF pathogens was recently stressed by Dagan et al, 29 who showed, in a summary of 907 AOM patients enrolled in double-tympanocentesis studies, that failure to eradicate MEF pathogens within the first few days of treatment led to a significant risk for clinical failure.
In this study, the total rate of culture-negative AOM cases at enrolment was unusually low (19%). To better understand how a low rate of culture-negative AOM cases at enrolment, by their superior clinical outcome at the end-of-treatment period, may bias the final interpretation of clinical outcome in antibiotic efficacy studies, we built a hypothetical antibiotic efficacy study where 2 drugs with different bacteriologic efficacy rates (90% and 60%) were analyzed. In this model, we chose to analyze the clinical outcome as function of the percentage of patients with culture-negative AOM initially enrolled (16.7% or 50%) from all patients enrolled, and showed how an increase in the number of culture-negative AOM cases enrolled leads to a major dilution of the results by considerably decreasing the overall rates of clinical failure and making the drug with low bacteriologic efficacy appear much more efficacious. Therefore, we propose, based on the results of this study, that culture-negative patients should be excluded from future antibiotic efficacy studies as soon as negative MEF cultures results are available and their antibiotic treatment should be discontinued.
